Knowledge on rare diseases and orphan drugs
COVID-19 & Rare diseases
Rare Diseases Resources for Refugees/Displaced Persons
Search for a rare disease
Methylmalonic acidemia with homocystinuria, type cblC
cblC type methylmalonic acidemia with homocystinuria is a form of methylmalonic acidemia with homocystinuria, an inborn error of vitamin B12 (cobalamin) metabolism characterized by megaloblastic anemia, lethargy, failure to thrive, developmental delay, intellectual deficit and seizures.
ORPHA:79282
Classification level: Subtype of disorder
- CblC defect
- Cobalamin C defect
- Combined defect in adenosylcobalamin and methylcobalamin synthesis, type cblC
- Methylmalonic aciduria with homocystinuria, type cblC
Prevalence: Unknown
Inheritance: Autosomal recessive
Age of onset: All ages
To date, over 500 cases of cblC have been reported, making it the most frequent type of methylmalonic acidemia with homocystinuria.
The disease typically presents with failure to thrive, acute neurological deterioration, intellectual deficit, lethargy, seizures, microcephaly, a salt-and-pepper retinopathy, and signs of megaloblastic anemia (pallor, fatigue, anorexia). Severe brain abnormalities including hydrocephalus, white matter abnormalities, cerebral atrophy, and unusual basal ganglia lesions are common. Onset of the disorder can be early (infantile) or late (juvenile or adult), with the late-onset form characterized by ataxia, dementia and psychosis.
cblC type methylmalonic acidemia with homocystinuria is caused by mutations in the MMACHC gene (1p36.3) and is transmitted in an autosomal recessive manner.
Last update: March 2012 - Expert reviewer(s): Dr David ROSENBLATT
: produced/endorsed by ERN(s)
: produced/endorsed by FSMR(s)
General public
Guidelines
Disease review articles
Further information on this disease
Patient-centred resources for this disease
Research activities on this disease
- Research project(s) (65)
- Clinical trial(s) (1)
- Biobank(s) (14)
- Registry(ies) (49)
- Network of experts (11)
Newborn screening